SEC Form 4
------------

## FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average t	ourden
hours per response:	0.5

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

-										
	L. Name and Address of Reporting Person <sup>*</sup> <u>Harmon Cyrus</u> (Last) (First) (Middle) C/O OLEMA PHARMACEUTICALS, INC. 512 2ND STREET, 4TH FLOOR		Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol Olema Pharmaceuticals, Inc. OLMA		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
	<u>armon Cyri</u>	<u>us</u>		<u></u> , <u></u> , ( )	X	Director	10% Owner			
<u> </u>		(=:)		-	X	Officer (give title below)	Other (specify below)			
(La	ist)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		,	,			
C/	O OLEMA P	HARMACE	UTICALS, INC.	11/29/2021		CHIEF TECHNOLO	OGY OFFICER			
51	2 2ND STRE	ET, 4TH FL	OOR							
(Str	eet)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi Line)	ividual or Joint/Group Fil	ing (Check Applicable			
SA		CA	94107		X	Form filed by One Re	eporting Person			
	RANCISCO			_		Form filed by More the Person	nan One Reporting			
(Cit	ty)	(State)	(Zip)							

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V Amount (A) or (D) Price		Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)		
Common Stock	11/29/2021		<b>S</b> <sup>(1)</sup>		400	D	\$24.76 <sup>(2)</sup>	1,051,146	D	
Common Stock								122,028	Ι	See Footnote <sup>(3)</sup>

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

				8		-									
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv Secu Acqu (A) of Dispo of (D) (Instr	of Expiration Date (Month/Day/Year) Securities Acquired (A) or Expiration Date (Month/Day/Year)		Expiration Date Amount of			8. Price of Derivative Security (Instr. 5)	tive derivative ity Securities	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

#### Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

2. The weighted average sale price for the transaction reported was \$24.76, and the range of prices were between \$24.75 and \$24.80. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.

# <u>/s/ John B. Moriarty, Jr.,</u>

12/01/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Attorney-in-Fact